Eva Vidacs
Impact in
- Hematology top 5%
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Genetics top 10%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
-
- Acute Myeloid Leukemia Research 4
- Multiple Myeloma Research and Treatments 2
- Oncology 5
- Cytokine Signaling Pathways and Interactions 2
- Peptidase Inhibition and Analysis 2
- Co-authors
- Ricky W. Johnstone (10 shared papers)Jake Shortt (4 shared papers)Gareth Peter Gregory (4 shared papers)Lev M. Kats (4 shared papers)Marcus Lefebure (3 shared papers)Simon J. Hogg (2 shared papers)Benjamin P. Martin (2 shared papers)Johannes A. Zuber (4 shared papers)
- Journals
- Cancer Research (2 papers)Cell Reports (2 papers)Leukemia (2 papers)Cancer Cell (1 paper)Nature Biotechnology (1 paper)
- Partner nations
- AustraliaUnited StatesAustria
In The Last Decade
Eva Vidacs
14 papers receiving 709 citations
Peers
Comparison fields: 5 of 64
- Hematology 232
- Genetics 120
- Oncology 205
- Molecular Biology 431
- Cancer Research 57
Countries citing papers authored by Eva Vidacs
This map shows the geographic impact of Eva Vidacs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Vidacs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Vidacs more than expected).
Fields of papers citing papers by Eva Vidacs
This network shows the impact of papers produced by Eva Vidacs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Vidacs. The network helps show where Eva Vidacs may publish in the future.
Co-authors
The 25 scholars most cited alongside Eva Vidacs, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 122 | |
| 2 | 2013 | 120 | |
| 3 | 2015 | 98 | |
| 4 | 2016 | 64 | |
| 5 | 2016 | 55 | |
| 6 | 2015 | 52 | |
| 7 | 2013 | 43 | |
| 8 | 2016 | 30 | |
| 9 | 2020 | 30 | |
| 10 | 2017 | 28 | |
| 11 | 2017 | 27 | |
| 12 | 2022 | 21 | |
| 13 | 2015 | 16 | |
| 14 | 2013 | 11 |
About Eva Vidacs
Eva Vidacs is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Pathology and Forensic Medicine, having authored 14 papers that have together received 717 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (6 papers), Histone Deacetylase Inhibitors Research (6 papers), Acute Myeloid Leukemia Research (4 papers), Ubiquitin and proteasome pathways (4 papers), Cytokine Signaling Pathways and Interactions (2 papers), Multiple Myeloma Research and Treatments (2 papers), Peptidase Inhibition and Analysis (2 papers) and Cancer Mechanisms and Therapy (1 paper). The work is most often cited by research in Hematology (232 citations), Genetics (120 citations), Oncology (205 citations), Molecular Biology (431 citations) and Cancer Research (57 citations). Eva Vidacs has collaborated with scholars based in Australia, United States and Austria. Frequent co-authors include Ricky W. Johnstone, Jake Shortt, Gareth Peter Gregory, Lev M. Kats, Marcus Lefebure, Simon J. Hogg, Benjamin P. Martin, Johannes A. Zuber, Omer Gilan and Mark A. Dawson. Their work appears in journals such as Cancer Research, Cell Reports, Leukemia, Cancer Cell and Nature Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.